KR920701432A - 뇌유도성 향신경성 인자 - Google Patents

뇌유도성 향신경성 인자

Info

Publication number
KR920701432A
KR920701432A KR1019910700432A KR910700432A KR920701432A KR 920701432 A KR920701432 A KR 920701432A KR 1019910700432 A KR1019910700432 A KR 1019910700432A KR 910700432 A KR910700432 A KR 910700432A KR 920701432 A KR920701432 A KR 920701432A
Authority
KR
South Korea
Prior art keywords
bdnf
nucleic acid
ngf
acid sequences
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019910700432A
Other languages
English (en)
Other versions
KR100188189B1 (en
Inventor
하이만 캐른
안델슨 랠프
얀코프로스 죠오지
바르디 예브스-알라닌
토옌 에프. 이 한스
흔 안드레아
로테스페히 프리드리히
엠.린드세이 로날드
호프테르 마그델레나
레이브로크 조카잉
에드가 데이비드
헨게르에르 바스티앙
린다호름 댄
자페르 프랜시스토
Original Assignee
막스-플란크-게젤샤프트 주르 포르데른 데르 비센샤프텐 이.브이.
리제네론 파라마큐티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/400,591 external-priority patent/US5180820A/en
Application filed by 막스-플란크-게젤샤프트 주르 포르데른 데르 비센샤프텐 이.브이., 리제네론 파라마큐티칼스 인코포레이티드 filed Critical 막스-플란크-게젤샤프트 주르 포르데른 데르 비센샤프텐 이.브이.
Publication of KR920701432A publication Critical patent/KR920701432A/ko
Application granted granted Critical
Publication of KR100188189B1 publication Critical patent/KR100188189B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1019910700432A 1989-08-30 1991-04-30 Brain derived neutrophic factor Expired - Fee Related KR100188189B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/400,591 US5180820A (en) 1989-08-30 1989-08-30 Brain-derived neurotrophic factor
US07/570,657 US5229500A (en) 1989-08-30 1990-08-20 Brain derived neurotrophic factor
PCT/US1990/004915 WO1991003568A1 (en) 1989-08-30 1990-08-29 Brain derived neurotrophic factor

Publications (2)

Publication Number Publication Date
KR920701432A true KR920701432A (ko) 1992-08-11
KR100188189B1 KR100188189B1 (en) 1999-06-01

Family

ID=27017110

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910700432A Expired - Fee Related KR100188189B1 (en) 1989-08-30 1991-04-30 Brain derived neutrophic factor

Country Status (20)

Country Link
US (2) US5229500A (ko)
EP (1) EP0440777B1 (ko)
KR (1) KR100188189B1 (ko)
CN (1) CN1124343C (ko)
AT (1) ATE148921T1 (ko)
AU (1) AU647412B2 (ko)
CA (1) CA2040412C (ko)
DE (1) DE69029934T2 (ko)
DK (1) DK0440777T3 (ko)
ES (1) ES2098271T3 (ko)
FI (1) FI105342B (ko)
HK (1) HK1006578A1 (ko)
IE (1) IE903128A1 (ko)
IL (1) IL95512A0 (ko)
LV (1) LV10725B (ko)
NO (1) NO303584B1 (ko)
PT (1) PT95152B (ko)
SG (1) SG46954A1 (ko)
SK (1) SK279668B6 (ko)
WO (1) WO1991003568A1 (ko)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844072A (en) * 1992-05-26 1998-12-01 University Of California Antibiotic cryptdin peptides and methods of their use
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
US6780837B1 (en) 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
AU2010592A (en) * 1991-05-20 1992-12-30 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
IE921315A1 (en) * 1991-07-03 1993-01-13 Regeneron Pharma Method and assay system for neurothrophin activity
RU94016525A (ru) * 1991-07-10 1996-06-10 Ридженерон Фармасьютикалз Способы лечения заболеваний двигательных нейронов
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
WO1993015608A1 (en) * 1992-02-14 1993-08-19 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
EP1415994A1 (en) * 1992-06-04 2004-05-06 The University Of Southern California Retinal pigmented epithelium derived neurotrophic factor
EP0573904B1 (en) * 1992-06-08 2001-09-26 Takeda Chemical Industries, Ltd. Therapeutic agent for neutropenia
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
ES2149823T3 (es) * 1992-09-03 2000-11-16 Univ California Factor y composiciones que afectan al tejido dorsal.
US20040224409A1 (en) * 1992-09-25 2004-11-11 Laurent Pradier Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
EP0632008B1 (en) * 1993-06-01 1998-02-04 Ono Pharmaceutical Co., Ltd. Pentanoic acid derivatives
WO1995006656A1 (en) * 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1995012686A1 (en) * 1993-11-03 1995-05-11 Cephalon, Inc. Method for screening for compounds which change the tyrosine hydroxylase content of intact cells in culture
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
EP0788351B1 (en) * 1994-11-10 2003-02-05 The University of Kentucky Research Foundation Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US6743628B1 (en) * 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
GB9608335D0 (en) * 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
ZA976326B (en) * 1996-07-19 1998-02-03 Amgen Inc Analogs of cationic proteins.
AU729459B2 (en) * 1996-11-15 2001-02-01 Genentech Inc. Purification of neurotrophins
AU718500B2 (en) 1997-01-23 2000-04-13 Sumitomo Pharmaceuticals Company, Limited Remedies for diabetes
AU1179699A (en) * 1997-11-11 1999-05-31 Universiteit Utrecht Genes with restricted expression in mesencephalic dopaminergic neurons
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
WO2000024415A2 (en) * 1998-10-28 2000-05-04 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU780408B2 (en) * 1999-06-08 2005-03-17 Calibre Biotechnology Pty Limited Small cyclic mimics of brain-derived neurotrophic factor (BDNF)
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
CA2383076A1 (en) * 1999-09-16 2001-03-22 Neurotrophic Bioscience, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
US20030036512A1 (en) * 2000-03-06 2003-02-20 Tsutomu Nakagawa Leptin-resistance amerliorating agents
US6784335B2 (en) 2000-06-29 2004-08-31 Deltagen, Inc. Transgenic mice containing BMP gene disruptions
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US7491810B2 (en) 2001-11-30 2009-02-17 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US7615676B2 (en) 2001-11-30 2009-11-10 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
AU2003286833A1 (en) * 2002-11-01 2004-06-07 University Of Medicine And Dentistry Of New Jersey A method for increasing synaptic growth or plasticity
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
CN102526706B (zh) * 2003-09-09 2014-07-30 智再如股份有限公司 牙周病和牙髓疾病的治疗剂以及治疗方法
EP3372614B1 (en) 2004-04-07 2022-06-08 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP2386654A1 (en) * 2005-05-02 2011-11-16 University of Southern California DNA Methylation markers associated with the CpG island methylator phenotype (cimp) in human colorectal cancer
EP2465924A3 (en) 2005-06-16 2013-01-02 Ramot at Tel-Aviv University Ltd. Isolated cells and populations comprising same for the treament of cns diseases
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20100021434A1 (en) * 2005-12-08 2010-01-28 Ramot At Tel Aviv University Ltd. Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases
US20100035877A1 (en) * 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
CA2748889A1 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
EP2594295A1 (en) 2011-11-16 2013-05-22 Servicio Andaluz De Salud Nerve implants based on a compacted biomaterial containing cells
AU2012346448B2 (en) 2011-12-02 2017-09-14 Armagen, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
CA3052936A1 (en) 2016-12-26 2018-07-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein of bdnf and anti-transferrin receptor antibody
JP2020531041A (ja) * 2017-08-28 2020-11-05 上海易楽生物技術有限公司 ポリペプチドとポリペプチドに結合される抗体
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
CN116543838B (zh) * 2023-07-05 2023-09-05 苏州凌点生物技术有限公司 一种生物基因选择表达概率的数据分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3123963C2 (de) * 1981-06-19 1985-05-15 Berchem & Schaberg Gmbh, 4650 Gelsenkirchen Gesteinsschneidkopf für einen Schneidkopf-Saugbagger
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins

Also Published As

Publication number Publication date
DK0440777T3 (da) 1997-04-21
LV10725B (en) 1995-12-20
CN1052142A (zh) 1991-06-12
PT95152B (pt) 1998-06-30
ES2098271T3 (es) 1997-05-01
SK422990A3 (en) 1999-02-11
ATE148921T1 (de) 1997-02-15
SK279668B6 (sk) 1999-02-11
DE69029934T2 (de) 1997-07-24
EP0440777A1 (en) 1991-08-14
SG46954A1 (en) 1998-03-20
CA2040412C (en) 2003-03-18
FI105342B (fi) 2000-07-31
EP0440777B1 (en) 1997-02-12
AU6337390A (en) 1991-04-08
US5229500A (en) 1993-07-20
WO1991003568A1 (en) 1991-03-21
IE903128A1 (en) 1991-03-13
IL95512A0 (en) 1991-06-30
AU647412B2 (en) 1994-03-24
FI912104A0 (fi) 1991-04-30
DE69029934D1 (de) 1997-03-27
HK1006578A1 (en) 1999-03-05
NO303584B1 (no) 1998-08-03
LV10725A (lv) 1995-06-20
EP0440777A4 (en) 1992-05-13
NO911689D0 (no) 1991-04-29
NO911689L (no) 1991-06-25
US5438121A (en) 1995-08-01
CA2040412A1 (en) 1991-03-01
KR100188189B1 (en) 1999-06-01
CN1124343C (zh) 2003-10-15
PT95152A (pt) 1991-05-22

Similar Documents

Publication Publication Date Title
KR920701432A (ko) 뇌유도성 향신경성 인자
GR900100653A (el) Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο.
Maruyama et al. A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells
EP0666912B1 (en) Modified ciliary neurotrophic factors
EP0448707A4 (en) Ciliary neurotrophic factor
FI103506B1 (fi) Menetelmä syklisten aminohappojohdannaisten valmistamiseksi ja menetelmässä käytettävä välituote
SI0852585T1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
KR100245250B1 (en) Human follicle stimulating hormone receptor
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
ES2009689A6 (es) Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima.
ATE317021T1 (de) Antisense modulierung von lfa-3
PT990000E (pt) Factor 3 de crescimento do tecido conjuntivo
Barde et al. Brain derived neurotrophic factor
AU5076393A (en) Proteins which regulate the expression of vertebrate MHC class II genes, DNA sequences encoding them and pharmaceutical compositions
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
ATE219513T1 (de) Molekulares klonieren von genomischen und cdna- sequenzen, die für zelluläre rezeptoren für poliovirus kodieren
DE68913212D1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
HK1007767B (en) Modified ciliary neurotrophic factors
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19910430

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950818

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19910430

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980528

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19981012

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19990111

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19990112

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20020105

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20030103

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20040106

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20050103

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20060106

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20070105

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20080109

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20090108

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20091229

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20101229

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20101229

Start annual number: 13

End annual number: 13

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20121209